A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial.

Exp Hematol Oncol · 2015 · PMC4835896 · PMID 27096106

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

showed a trendP = 0.21not close (p > 0.1)

ORR among patients who had previously received thalidomide and those who did not receive thalidomide was 33 % (4/12 patients, all PRs) and 46 % (11/24 patients, with 1 CR and 10 PRs), respectively, with no significant difference between two groups (P = 0.72), although the latter showed a trend toward longer PFS (3.3 months versus not reached, P = 0.21).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.